BR0311593A - Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc - Google Patents

Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc

Info

Publication number
BR0311593A
BR0311593A BR0311593-3A BR0311593A BR0311593A BR 0311593 A BR0311593 A BR 0311593A BR 0311593 A BR0311593 A BR 0311593A BR 0311593 A BR0311593 A BR 0311593A
Authority
BR
Brazil
Prior art keywords
treatment
receptor modulators
sulphonyl
indole derivatives
disorders
Prior art date
Application number
BR0311593-3A
Other languages
English (en)
Inventor
Robin Douglas Clark
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0311593A publication Critical patent/BR0311593A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS DE 1-SULFONIL-4-AMINOALCOXI INDOL COMO MODULADORES DE RECEPTOR 5-HT6 PARA O TRATAMENTO DOS DISTúRBIOS DE SNC". A presente invenção refere-se a um composto de fórmula (I): um sal farmaceuticamente aceitável ou seu produto, no qual R^ 1^, R^ 2^, R^ 3^ , R^ 4^, R^ 5^, R^ 6^, e n são conforme definidos aqui. A presente invenção também refere-se a composições compreendendo métodos para seu uso, e métodos para preparação de compostos de fórmula I.
BR0311593-3A 2002-06-05 2003-05-28 Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc BR0311593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38604902P 2002-06-05 2002-06-05
PCT/EP2003/005604 WO2003104193A1 (en) 2002-06-05 2003-05-28 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders

Publications (1)

Publication Number Publication Date
BR0311593A true BR0311593A (pt) 2005-04-26

Family

ID=29736132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311593-3A BR0311593A (pt) 2002-06-05 2003-05-28 Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc

Country Status (13)

Country Link
US (1) US6774241B2 (pt)
EP (1) EP1513809A1 (pt)
JP (1) JP4390698B2 (pt)
KR (1) KR100657056B1 (pt)
CN (1) CN1293053C (pt)
AR (1) AR039957A1 (pt)
AU (1) AU2003237705B2 (pt)
BR (1) BR0311593A (pt)
CA (1) CA2485725A1 (pt)
MX (1) MXPA04012122A (pt)
PL (1) PL374401A1 (pt)
RU (1) RU2323927C2 (pt)
WO (1) WO2003104193A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
PL376479A1 (en) * 2002-10-18 2005-12-27 F.Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
CN102114244A (zh) 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
RU2294325C2 (ru) * 2005-04-04 2007-02-27 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУВПО "КубГТУ") Способ получения 4-[1-(толил-4-сульфонил)-1h-индолил-2]-бут-3-ен-2-онов
EA013875B1 (ru) 2005-08-12 2010-08-30 Сувен Лайф Сайенсиз Лимитед Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
WO2007020654A1 (en) * 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
EP2046741B1 (en) 2006-07-03 2012-10-31 Proximagen Ltd. Indoles as 5-ht6 modulators
CN101631787A (zh) * 2007-03-13 2010-01-20 比奥维特罗姆上市公司 用于肥胖症治疗的三环异喹啉衍生物
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
KR20090128426A (ko) 2007-03-23 2009-12-15 애보트 게엠베하 운트 콤파니 카게 세로토닌 5―ht6 수용체의 조절에 반응하는 장애를 치료하는 데 적합한 퀴놀린 화합물
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
KR101558193B1 (ko) * 2007-08-21 2015-10-12 세노믹스, 인코포레이티드 인간 t2r 쓴맛 수용체 및 이의 용도
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN102344402B (zh) * 2010-07-30 2015-01-07 中国人民解放军军事医学科学院毒物药物研究所 苯并氮杂环羟乙基胺类化合物、其制备方法和用途
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN115894325B (zh) * 2022-09-20 2025-05-27 徐州医科大学 一种含有芳基哌嗪结构的衍生物、组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1139760A (en) 1979-03-07 1983-01-18 Makiko Sakai 1,4-dioxaspiro¬4,5| decene compounds
JPH04134064A (ja) 1990-09-25 1992-05-07 Otsuu Kenkyusho 4―アルコキシインドール誘導体の製造方法
WO1995017398A1 (en) 1993-12-21 1995-06-29 Smithkline Beecham Plc Indole, indoline and quinoline derivatives with 5ht1d (anti-depressive) activity
EP0871442A1 (en) 1996-01-09 1998-10-21 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
US5958965A (en) 1996-08-27 1999-09-28 American Home Products Corporation 4-aminoethoxy indoles
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002220715A1 (en) * 2000-11-24 2002-06-03 Smithkline Beecham Plc Indolsulfonyl compounds useful in the treatment of cns disorders
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002085853A2 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2444095A1 (en) * 2001-04-20 2002-10-31 Wyeth Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
AU2003237705B2 (en) 2009-07-30
RU2004139050A (ru) 2005-09-10
JP4390698B2 (ja) 2009-12-24
CN1293053C (zh) 2007-01-03
KR20050010861A (ko) 2005-01-28
PL374401A1 (en) 2005-10-17
EP1513809A1 (en) 2005-03-16
US6774241B2 (en) 2004-08-10
KR100657056B1 (ko) 2006-12-13
AU2003237705A1 (en) 2003-12-22
RU2323927C2 (ru) 2008-05-10
JP2005533048A (ja) 2005-11-04
CN1659141A (zh) 2005-08-24
US20030229069A1 (en) 2003-12-11
WO2003104193A1 (en) 2003-12-18
AR039957A1 (es) 2005-03-09
MXPA04012122A (es) 2005-04-19
CA2485725A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
BR0311593A (pt) Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
WO2001090104A3 (en) -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
WO2002024700A3 (en) SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
EA200600892A1 (ru) Новые хинолиновые производные
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
TW200612936A (en) Indole derivatives
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
MX9301197A (es) Derivados de indol.
HU907025D0 (en) Process for producing substituted n-(imidazolyl-alkyl)-alanine derivatives and pharmaceutical preparatives containing these compounds as active substance
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.